Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2018 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion

CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
March 05, 2018 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018

CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
February 15, 2018 11:58 ET | Source: Agios Pharmaceuticals, Inc.

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

– PDUFA date set for August 21, 2018 – CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer...
February 14, 2018 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2017 Financial Results

– All 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios’ Discovery Platform and NDA Submission for Second Product Candidate, Ivosidenib, for IDH1m R/R AML – – 2018...
January 31, 2018 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
January 23, 2018 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
January 18, 2018 20:43 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Pricing of $475 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 7,089,553 shares of common stock...
January 17, 2018 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $400 million...
January 08, 2018 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value

- Ivosidenib NDA for IDH1m R/R AML Submitted in December for Priority Review; Multiple Pivotal Trials Ongoing or Planned for Ivosidenib in Frontline AML and Solid Tumors Including 4Q 2018 Initiation...
January 02, 2018 07:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018

CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...